COVID vaccines in HIV-Positive recipients: Need for more data from the Novavax South Africa study and with other vaccine platforms
By Daniel R. Lucey MD, MPH, FIDSA The Jan. 28 Novavax press release that included preliminary results from its COVID-19 vaccine Phase 2b trial in South Africa appears to contain a significant difference in efficacy between volunteers who were HIV-positive and HIV-negative. If verified, then the implications warrant sustained attention for this protein-based adjuvanted COVID-19 […]
